Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Rhea-AI Summary

Passage Bio, a clinical stage genetic medicines company focused on central nervous system (CNS) disorders, announced that its CEO William Chou, M.D., and CTO Alex Fotopoulos will participate in a virtual fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 24, 2023, at 3:30 p.m. ET.

The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days after. Passage Bio is dedicated to developing therapies for CNS diseases, currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia, and has a robust preclinical pipeline targeting amyotrophic lateral sclerosis and Huntington’s disease. The company collaborates with the University of Pennsylvania’s Gene Therapy Program, enhancing its research capabilities and access to innovative gene therapy candidates.

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer, and Alex Fotopoulos, chief technical officer, will participate in a virtual fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 3:30 p.m. ET.

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia and our preclinical pipeline, including programs in amyotrophic lateral sclerosis and Huntington’s disease. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Passage Bio Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com 

FAQ

What will Passage Bio present at the Chardan Summit on April 24, 2023?

Passage Bio's CEO and CTO will discuss the company's advancements in gene therapies for CNS disorders.

Where can I watch the Passage Bio event on April 24, 2023?

The event can be viewed via a live webcast on Passage Bio's Investor Relations website.

What are the key CNS disorders Passage Bio is focusing on?

Passage Bio is focusing on GM1 gangliosidosis, frontotemporal dementia, amyotrophic lateral sclerosis, and Huntington's disease.

How long will the webinar replay be available after the event?

The replay of the presentation will be available for 30 days following the event.

What is the significance of the collaboration with the University of Pennsylvania for Passage Bio?

This collaboration enhances Passage Bio's access to gene therapy innovations and supports its clinical research efforts.